In this article, we will list the 5 Most Undervalued NASDAQ Stocks to Buy Right Now. Please visit 10 Most Undervalued NASDAQ Stocks to Buy Right Now to see the extended list and the methodology behind it.
5. Viatris Inc. (NASDAQ:VTRS)
Number of Hedge Fund Holders: 60
Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, demonstrating a statistically significant 33.75% reduction in urine protein-to-creatinine ratio after nine months of treatment, while also showing improvements in kidney function and sustained proteinuria reduction.
The clinical profile observed in Japanese patients was consistent with results from previous global studies, and the treatment was reported to be well tolerated with no participants progressing to dialysis, kidney transplant, or severe renal impairment during the study. These findings represent a significant milestone for Viatris, as the company seeks to address the high incidence of IgAN in Japan, where it is a leading cause of chronic glomerulonephritis and end-stage renal disease.
Building on these results, Viatris Inc. (NASDAQ:VTRS) is now targeting the submission of a NDA in Japan by the end of 2026. If approved, VR-205 would become the first IgAN-specific, targeted-release budesonide oral therapy in the country, providing a potentially disease-modifying treatment option for a condition that currently lacks curative therapies.
Viatris Inc. (NASDAQ:VTRS) is a healthcare company operating across Japan, Europe, Hong Kong, Africa, North America, Australia, the Middle East, New Zealand, Taiwan, Latin America, China, and the rest of Asia. The company operates through the JANZ, Developed Markets, Emerging Markets, and Greater China segments.
4. Biogen Inc. (NASDAQ:BIIB)
Number of Hedge Fund Holders: 64
Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase II studies for Empaveli in treating delayed graft function and focal segmental glomerulosclerosis, citing strategic evaluations and recruitment challenges.
While the future of Apellis’ preclinical assets (such as its RNA-based therapies and gene-editing project) remains unclear, Biogen is maintaining its focus on a key Phase II trial for its eye disease therapy, Syfovre, in combination with an RNA interference inhibitor. This move indicates that Biogen’s primary interest lies in the established commercial value of the pegcetacoplan franchise, which is marketed as both Empaveli and Syfovre.
Biogen Inc.’s (NASDAQ:BIIB) strategic thinning of the pipeline appears designed to prioritize the most profitable assets acquired in the deal, with forecasts suggesting the pegcetacoplan franchise could generate $785 million by 2032. Although the company has not provided specific details regarding every program slated for closure, the shifts underscore a broader consolidation effort following the high-profile rare disease buyout.
Biogen Inc. (NASDAQ:BIIB) is a biopharmaceutical firm that works on identifying, making, and providing drugs for neurological and neurodegenerative diseases.
3. Gilead Sciences Inc. (NASDAQ:GILD)
Number of Hedge Fund Holders: 77
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate authorized for this setting regardless of PD-L1 status.
The approval follows successful Phase 3 trials showing significantly improved progression-free survival and more durable responses compared to standard chemotherapy. Based on these results, the National Comprehensive Cancer Network now lists Trodelvy as a category 1 preferred first-line treatment.
This milestone expands Trodelvy’s clinical utility, building on its existing use in later-stage breast cancer treatments. With over 75,000 patients treated globally, this new indication provides a vital standard-of-care option for a disease that has historically lacked diverse first-line therapies.
Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.
2. Booking Holdings Inc. (NASDAQ:BKNG)
Number of Hedge Fund Holders: 95
Booking Holdings Inc. (NASDAQ:BKNG) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On July 3, Checkout.com announced a new partnership with digital travel platform Agoda, a subsidiary of Booking Holdings, to optimize payment processing across more than six million properties worldwide. By integrating Checkout.com’s infrastructure, Agoda aims to ensure reliable transaction performance across diverse markets, currencies, and high-demand periods.
A central component of this collaboration is the implementation of Intelligent Acceptance, Checkout.com’s AI-powered tool that uses real-time data to optimize transaction routing and approval rates. These enhancements, alongside network tokenization and real-time account updates, help minimize failed transactions and reduce false declines within Agoda’s complex global payment ecosystem.
Additionally, the partnership strengthens Agoda’s virtual card issuing capabilities to streamline payments to its global supplier network. Through this single, connected platform, Agoda maintains consistent oversight and operational control, ensuring the seamless processing of supplier payments at scale.
Booking Holdings Inc. (NASDAQ:BKNG) provides online travel and related solutions through its brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. The company is based in Norwalk, Connecticut, and was founded in July 1997 by Jay Scott Walker.
1. Sandisk Corporation (NASDAQ:SNDK)
Number of Hedge Fund Holders: 114
Sandisk Corporation (NASDAQ:SNDK) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On July 3, Kioxia and Sandisk announced the start of production for their 10th-generation 3D flash memory technology at the Fab2 (K2) facility in Kitakami, Japan. This milestone follows the plant’s opening in September 2025 and is part of a multi-year effort to increase manufacturing capacity to meet rising global demand for NAND flash memory, particularly for AI-driven applications.
The K2 facility uses advanced CBA technology, earthquake-resistant architecture, and artificial intelligence to maximize manufacturing efficiency and energy savings. By scaling production of both 8th- and 10th-generation products, the companies aim to provide high-performance, high-capacity, and low-power storage solutions that support their long-term growth targets.
This launch underscores the strength of the companies’ long-standing joint venture, which was recently extended through December 2034. Through continued investments in the Kitakami plant, Kioxia and Sandisk Corporation (NASDAQ:SNDK) plan to maintain their competitiveness in the semiconductor industry while fostering economic development and strengthening US-Japan manufacturing relations.
Sandisk Corporation (NASDAQ:SNDK) develops and manufactures data storage devices and solutions based on NAND flash technology. Its offerings include solid-state drives, embedded products, removable cards, USB drives, and wafers and components, sold through consumer brands and global franchises.
While we acknowledge the potential of SNDK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNDK and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Penny Stocks With Explosive Growth Potential and 8 Oversold Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
